NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Viking Therapeutics, Inc. (VKTX) Stock Analysis

Viking Therapeutics, Inc. (VKTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

VKTX

$26.38

−$0.33 (−1.24%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VKTX with… →

VKTX Key Statistics

As of Oct 21, 2026
Trading
Open
$26.78
Previous Close
$26.71
Day's Range
26.31–27.29
52-Week Range
24.94–43.15
Volume
3.27M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.65
Valuation
Market Cap
$3.35B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.67
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$359.64M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
127.17M
1-Year Return
−20.01%
Dividend and dates
Earnings Date
October 28, 2026
Avg Volume
4.55M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, VKTX closed at $26.38, −20.01% over 1 year.

Viking Therapeutics, Inc. (VKTX) has a market capitalization of $3.35B.

In fiscal 2025, VKTX reported revenue of $0.00.

VKTX Stock Return by Calendar Year

Viking Therapeutics, Inc. (VKTX) 10-year return: what $10,000 became

1 year
$10,000 $7,999
−20.01%
5 years
$10,000 $46,281
+362.81%
10 years
$10,000 $237,658
+2,276.58%

If you had invested $10,000 in Viking Therapeutics, Inc. (VKTX) 10 years ago, at the close on October 21, 2016, it would have been worth $237,658 at the close on October 21, 2026: +2,276.58% in total, +37.28% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−25.01%
2025−12.57%
2024+116.23%
2023+97.98%
2022+104.35%
2021−18.29%
2020−29.80%
2019+4.84%
2018+88.42%
2017+241.18%
2016 (partial year)−12.50%

As of October 21, 2026.

VKTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$359.64M—
2024$0.00−$109.96M—
2023$0.00−$85.90M—
2022$0.00−$68.87M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$393.34M−$359.64M—
2024$0.00—−$150.92M−$109.96M—
2023$0.00—−$100.83M−$85.90M—
2022$0.00—−$70.36M−$68.87M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Viking Therapeutics, Inc. (VKTX) at $3.35B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 65 employees.

The 52-week range on file runs from $24.94 to $43.15. VKTX last closed at $26.38 on October 21, 2026. That is −$0.33 (−1.24%) against the previous close. The latest close sits 5.77% above that 52-week low.

Financial Health

In fiscal 2025, Viking Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $359.64M. Trailing earnings per share are −4.67.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 0.65. Daily returns over the trailing 10 years annualize to a volatility of 97.94%. Over the trailing twelve months the total return is −20.01%. Measured over 10 years, that is +37.28% a year compounded.

Growth & Income

The record shows no dividend for VKTX.

The strongest complete calendar year on file is 2017 at +241.18%; the weakest is 2020 at −29.80%. Of the 9 complete calendar years on file, 6 finished higher. 2026 is still running; the total return is −25.01% year to date.

Peer Comparison

Viking Therapeutics, Inc. (VKTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Viking Therapeutics, Inc. VKTX $3.35B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Viking Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Visit website →